FCG Investment Co Has $330,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

FCG Investment Co increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 13.8% during the fourth quarter, HoldingsChannel.com reports. The fund owned 1,267 shares of the medical research company’s stock after purchasing an additional 154 shares during the period. FCG Investment Co’s holdings in Amgen were worth $330,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in Amgen during the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC bought a new stake in shares of Amgen during the 2nd quarter worth $30,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the 3rd quarter valued at $29,000. Matrix Trust Co bought a new position in Amgen in the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen during the 3rd quarter worth $56,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 1.6 %

Shares of NASDAQ:AMGN opened at $277.88 on Friday. The company’s fifty day moving average is $271.91 and its 200-day moving average is $306.43. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a market capitalization of $149.37 billion, a PE ratio of 35.58, a P/E/G ratio of 2.79 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business earned $4.96 earnings per share. Equities research analysts predict that Amgen Inc. will post 19.57 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen’s dividend payout ratio is 115.24%.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMGN. Royal Bank of Canada lowered their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 27th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners cut their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Piper Sandler Companies restated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, Citigroup cut their target price on shares of Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.